
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is well-positioned for success with its innovative mAb therapies addressing high-need viral infectious diseases. The company's LIBERTY Phase 3 trial presents a compelling opportunity to gather controlled data on VYD2311's safety and tolerability compared to mRNA vaccines, potentially positioning it as a favorable alternative. Additionally, Invivyd's well-designed DECLARATION trial and strong payer and policy feedback suggest a positive commercial outlook for its flagship product.
Bears say
Invivyd is a biopharmaceutical company with a negative outlook as its success is heavily dependent on the success of its lead product, PEMGARDA, and the potential success of its other antibody candidates is uncertain. Additionally, the company's valuation is highly dependent on the risk-adjusted discounted cash flow methodology, with a high risk adjustment for its COVID prophylaxis franchise. The company also faces various risks, including clinical development, competitor, and pricing risks, which could impact its ability to achieve its price target. Moreover, while recent safety updates have been positive, there is still uncertainty around the effectiveness of their monoclonal antibodies against evolving COVID-19 strains, and any unexpected changes could impact the company's future prospects.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares